Kristin Eivindvik - PCI Biotech Chief Officer

All Insiders . Norway . 
Stock . PCI Biotech Holding . Stakeholders . Insider . Kristin Eivindvik
PCIB Stock  NOK 1.32  0.08  5.71%   

Insider

Kristin Eivindvik is Chief Officer of PCI Biotech Holding
Age 62
Phone(47) 67 11 54 00
Webwww.pcibiotech.com

PCI Biotech Management Efficiency

The company has return on total asset (ROA) of (0.3973) % which means that it has lost $0.3973 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.7359) %, meaning that it generated substantial loss on money invested by shareholders. PCI Biotech's management efficiency ratios could be used to measure how well PCI Biotech manages its routine affairs as well as how well it operates its assets and liabilities.
PCI Biotech Holding has accumulated 1.28 M in total debt with debt to equity ratio (D/E) of 0.5, which is about average as compared to similar companies. PCI Biotech Holding has a current ratio of 15.92, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist PCI Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, PCI Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like PCI Biotech Holding sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for PCI to invest in growth at high rates of return. When we think about PCI Biotech's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Klas StlsnesJaeren Sparebank
N/A
Inger DrengstigJaeren Sparebank
N/A
Annikken KlukenAasen Sparebank
N/A
Rune RasmussenAasen Sparebank
N/A
Jethro HolterArcticzymes Technologies ASA
51
Anne JorgensenInstabank ASA
N/A
Kjersti FuglestadJaeren Sparebank
N/A
Borge SorvollArcticzymes Technologies ASA
48
Kjersti HusbyAasen Sparebank
N/A
Darren EllisArcticzymes Technologies ASA
N/A
Kjetil KnudsenInstabank ASA
N/A
Oddgeir TeigenJaeren Sparebank
N/A
Marit LorentzenArcticzymes Technologies ASA
55
Dirk HahneiserArcticzymes Technologies ASA
55
Alexander BjornaArcticzymes Technologies ASA
N/A
Geir TjlandJaeren Sparebank
N/A
Ingrid NestvoldAasen Sparebank
N/A
Farzad JalilyInstabank ASA
N/A
Hanne AspasAasen Sparebank
N/A
Trude HynneAasen Sparebank
N/A
Magne StangelandJaeren Sparebank
N/A
PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization technology platform. PCI Biotech Holding ASA was founded in 2000 and is headquartered in Oslo, Norway. PCI BIOTECH operates under Pharmaceuticals And Biosciences classification in Norway and is traded on Oslo Stock Exchange. It employs 11 people. PCI Biotech Holding (PCIB) is traded on Oslo Stock Exchange in Norway and employs 14 people.

Management Performance

Return On Equity-0.74
Return On Asset-0.4

PCI Biotech Holding Leadership Team

Elected by the shareholders, the PCI Biotech's board of directors comprises two types of representatives: PCI Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of PCI. The board's role is to monitor PCI Biotech's management team and ensure that shareholders' interests are well served. PCI Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, PCI Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
Lucy Wabakken, Acting CDO
Anders Hgset, Chief Officer
Ronny Skuggedal, CEO CFO
Kristin Eivindvik, Chief Officer

PCI Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is PCI Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-0.74
Return On Asset-0.4
Operating Margin(15.29) %
Current Valuation25.47 M
Shares Outstanding37.33 M
Shares Owned By Insiders31.97 %
Shares Owned By Institutions6.90 %
Price To Earning(10.88) X
Price To Book1.44 X
Price To Sales18.74 X

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Other Information on Investing in PCI Stock

PCI Biotech financial ratios help investors to determine whether PCI Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in PCI with respect to the benefits of owning PCI Biotech security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY